×
About 303,048 results

A Bigger Red Flag for CAR-T's Toll on the Heart, Lungs
https://www.medpagetoday.com/hematologyoncology/hematology/95248

Oct 25th, 2021 - Stronger signals of cardiovascular and pulmonary risk emerged in the largest postmarketing study of chimeric antigen receptor (CAR) T-cell therapy to date. In the FDA Adverse Event Reporting System (FAERS), the 2,657 patient reports for axicabtagene-ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) were associated with significant overreporting of: Compared with tisagenlecleucel, axicabtagen...

Convenience, not outcomes may drive robot-assisted surgeries
https://www.mdedge.com/hematology-oncology/article/247841/gastrointestinal-cancer/convenience-not-outcomes-may-drive-robot
Neil Osterweil

Oct 25th, 2021 - The use of robotically assisted surgical devices for benign and malignant tumors is here to stay, but the decision to perform robot-assisted surgery should be driven by clinical outcomes, not convenience, physicians say. “The problem in minimally invasive surgery, especially in cancer surgery, is that the concept has been flip-flopped,” said Hooman Noorchashm, MD, PhD, a retired cardiothoracic.

Fauci in the Doghouse; SCOTUS to Review Texas Abortion Law; Public Health's Downfall
https://www.medpagetoday.com/infectiousdisease/covid19/95235

Oct 25th, 2021 - Note that some links may require registration or subscription. NIH officials admitted that they funded research to the Wuhan Institute of Virology that enhanced bat coronaviruses, but insisted there were too many genetic differences for one of those viruses to have led to the origin of the COVID pandemic. (Vanity Fair) Meanwhile, 24 legislators sent a letter to NIAID Director Anthony Fauci, MD,...

Nivolumab Prolongs PFS, OS in Relapsed Malignant Mesothelioma
https://www.cancertherapyadvisor.com/home/cancer-topics/lung-cancer/mesothelioma-nivolumab-prolongs-survival-pfs-treatment-risk/

Oct 25th, 2021 - Nivolumab significantly prolongs survival outcomes, when compared with placebo, in patients with relapsed malignant mesothelioma, according to results of the CONFIRM trial. “To our knowledge, the CONFIRM trial is the first randomized, phase 3 study to show improved overall survival in patients with relapsed malignant pleural and peritoneal mesothelioma,” the researchers wrote in The Lancet Onco...

Diagnosis and Management of Differentiation Syndrome in Patients With Acute Myeloid Leukemia
https://www.cancertherapyadvisor.com/home/cancer-topics/hematologic-cancers/differentiation-syndrome-acute-leukemia-diagnosis-management-treatment/

Oct 25th, 2021 - Differentiation syndrome (DS), also termed retinoic acid syndrome or all-trans retinoic acid (ATRA) syndrome, is a recognized complication in patients undergoing treatment with newer targeted therapies for acute myeloid leukemia (AML), such as FLT3 and IDH inhibitors.1 Evidence suggests the syndrome results from a severe systemic inflammatory response induced by a variety of inflammatory mediat...

MRD Assessment Can Guide Treatment Discontinuation in CLL/SLL
https://www.cancertherapyadvisor.com/home/cancer-topics/chronic-lymphocytic-leukemia/mrd-minimal-residual-disease-chronic-leukemia-treatment-cll-sll-risk/

Oct 25th, 2021 - Minimal residual disease (MRD) assessment can be used to guide treatment discontinuation in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), according to phase 2 results published in the Journal of Clinical Oncology. The phase 2 CAPTIVATE trial (ClinicalTrials.gov Identifier: NCT02910583) was designed to test MRD-guided treatment discontinuation after first-line ...

Assessing Priorities in End-of-Life Care for Children With Cancer
https://www.cancertherapyadvisor.com/home/cancer-topics/pediatric-cancer/end-life-care-cancer-children-assess-priorities-treatment-risk/

Oct 25th, 2021 - A study of end-of-life care in children with cancer suggests that health care resource use may be of less importance to stakeholders than patient-reported outcomes. The results of this study were reported in JCO Oncology Practice. “Previous studies suggest that receipt of intensive hospital care near end of life may be associated with decreased quality of life for adults with cancer and complic...

HSCT After COVID-19 Appears Safe, but Most Patients Lose SARS-CoV-2 Antibodies
https://www.cancertherapyadvisor.com/home/cancer-topics/hematologic-cancers/cancer-stem-cell-covid19-hsct-safe-antibodies-treatment-risk/

Oct 25th, 2021 - A new study suggests that autologous or allogeneic hematopoietic stem cell transplant (HSCT) after SARS-CoV-2 infection is safe, but many patients do not maintain anti-SARS-CoV-2 antibodies. The retrospective study was published in Transplantation and Cellular Therapy. Researchers evaluated the medical charts of 15 consecutive patients with hematologic malignancies who had developed asymptomati...

COVID-19 mortality higher in patients with active AML vs. those in remission
https://www.mdedge.com/hematology-oncology/article/247825/aml/covid-19-mortality-higher-patients-active-aml-vs-those

Oct 24th, 2021 - Key clinical point: The source of COVID-19 in most patients with acute myeloid leukemia (AML) was presumed to be in-hospital transmission with mortality because COVID-19 was higher in patients with active disease than those in remission. Major finding: The source of infection was in-hospital transmission in 63% of cases.

LDAC+venetoclax shows promise as frontline therapy in treatment-naive AML patients unfit for IC
https://www.mdedge.com/hematology-oncology/article/247822/aml/ldacvenetoclax-shows-promise-frontline-therapy-treatment

Oct 24th, 2021 - Key clinical point: Combination of low-dose cytarabine (LDAC) with venetoclax vs. placebo improved survival and treatment response in treatment-naive patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy (IC).

R/R AML: Mito-FLAG improves response, but allo-HSCT remains essential for prolonged survival
https://www.mdedge.com/hematology-oncology/article/247821/aml/r/r-aml-mito-flag-improves-response-allo-hsct-remains

Oct 24th, 2021 - Key clinical point: Salvage chemotherapy with a combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (Mito-FLAG) was effective and well-tolerated in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). However, consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) is essential for long-term disease-free surv.

Intensification of induction II does not improve outcomes in pediatric high-risk AML
https://www.mdedge.com/hematology-oncology/article/247820/aml/intensification-induction-ii-does-not-improve-outcomes

Oct 24th, 2021 - Key clinical point: Intensification of induction II chemotherapy with mitoxantrone and high-dose cytarabine (MA) did not improve survival, but increased toxicity in pediatric patients with high-risk acute myeloid leukemia (AML) vs. cytarabine/daunorubicin/etoposide (ADE).

Addition of quizartinib to LDAC improves outcomes in older patients with FLT3-ITD-mutated AML
https://www.mdedge.com/hematology-oncology/article/247819/aml/addition-quizartinib-ldac-improves-outcomes-older-patients

Oct 24th, 2021 - Key clinical point: Addition of quizartinib to low-dose ara-C (LDAC) vs. LDAC alone improved survival and response in older patients with acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3-internal tandem duplication ( FLT3-ITD) mutation who were unfit for intensive chemotherapy (IC).

The pancreatic fistula paradox in pancreatic cancer patients undergoing pancreatectomy
https://www.mdedge.com/gihepnews/article/247817/exocrine-pancreatic-insufficiency/pancreatic-fistula-paradox-pancreatic

Oct 24th, 2021 - Key clinical point: Among patients with pancreatic cancer undergoing pancreatectomy, pancreatic fistula (PF) did not affect postoperative pancreatic exocrine function. However, preserved or accelerated exocrine function post-pancreatectomy may cause PF.

EPI in patients with pancreatic cancer undergoing carbon ion radiotherapy
https://www.mdedge.com/gihepnews/article/247814/exocrine-pancreatic-insufficiency/epi-patients-pancreatic-cancer-undergoing

Oct 24th, 2021 - Key clinical point: Exocrine pancreatic insufficiency (EPI) developed early during carbon ion radiotherapy among patients with pancreatic cancer, suggesting pancreatic sensitivity to carbon-ion beams. Major finding: Overall, 57.

CML: Better response with first-line new-generation TKI therapy vs. imatinib
https://www.mdedge.com/hematology-oncology/article/247810/cml/cml-better-response-first-line-new-generation-tki-therapy-vs

Oct 24th, 2021 - Key clinical point: In real-life settings, patients with chronic myeloid leukemia (CML) in accelerated or chronic phase treated with new-generation tyrosine kinase inhibitor (NG-TKI) therapy in first line were more likely to achieve major molecular response (MMR) vs. those treated with imatinib.

No effect of bDMARD treatment on risk for cancer recurrence or new cancer in RA
https://www.mdedge.com/rheumatology/article/247801/rheumatoid-arthritis/no-effect-bdmard-treatment-risk-cancer-recurrence

Oct 24th, 2021 - not seem to be associated with an elevated risk for recurrent or new cancer in patients with rheumatoid arthritis (RA) and a history of cancer. Major finding: The risk for recurrent or new cancer was not significantly higher in patients with RA receiving bDMARDs (relative risk [RR], 1.

I Am CDC - Catherine Jamal
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/415945

Hi! I'm a Digital Media Lead here at CDC. I grew up in Atlanta and, like most locals, was in awe of this exciting, larger-than-life place that I drove by nearly every day. I joined CDC 16 years ago, after graduating with degrees in computer science and psychology. One of my first jobs was helping CDC move into the digital age. It has been awesome! Over the years, I've helped create web sites, s...

La prevención del cáncer empieza desde la niñez
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/393666

Usted puede reducir el riesgo de que sus hijos tengan cáncer en el futuro al hacer que les pongan la vacuna contra el VPH y al ayudarlos a que tomen decisiones saludables.

Cómo mantenerse sano durante y después del tratamiento contra el cáncer
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/393667

Pacientes de cáncer: vean consejos sobre cómo mantenerse físicamente, mentalmente y emocionalmente sanos durante y después del tratamiento contra el cáncer.